# Welcome to the Sentinel Innovation Center Webinar Series

### The webinar will begin momentarily

- Please visit <u>www.sentinelinitiative.org</u> for recordings of past sessions and details on upcoming webinars.
- Note: closed-captioning for today's webinar will be available on the recording posted at the link above.



## Portability and Scalability of Computable Phenotypes: Trade Offs and Trajectories

Jon Duke, MD Director, Center for Health analytics and Informatics Georgia Tech August 24th 2020





Research Institute

### **Conflicts of Interest**

- CHAI receives funding from organizations including FDA and CDC to conduct work that relates to the topics discussed in today's webinar
- No personal financial COIs

### Overview

- Constructing phenotypes is a cornerstone activity in health data analytics, whether for research, quality, safety, cost or clinical objectives
- We will explore aspects of phenotype *portability* and *scalability,* with particular emphasis on recent policy, standards, and tools that can inform phenotyping decisions
- A key goal is to enable broader use of electronic health data beyond current commonly used sources

### What's a phenotype?

- A phenotype is a logical definition of a clinical event, state, or or characteristic of interest
  - "Computable" indicates that the phenotype is machine-interpretable so that the query that it be run on a data source to find matching patients
- In safety contexts, phenotypes often define exposures (eg patients who received a given drug) and outcomes (eg patients who had a myocardial infarction)

### Portability and Scalability

- Portability refers to the performance of a phenotype in generating consistent cohorts across diverse sites
  - ie, did you find the patients you are looking for
  - Reflects the design of the phenotype content and logic
- Scalability refers to the ability for a phenotype to be run on a wide range of sites and data sources
  - Reflects infrastructure, platform, adoption etc

Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis

Myrlene Sanon Aigbogun<sup>1\*</sup>, Robert Stellhorn<sup>1</sup>, Ann Hartry<sup>2</sup>, Ross A. Baker<sup>3</sup> and Howard Fillit<sup>4,5</sup>

#### Patient population

Selected patients had at least one International Classification of Diseases, Ninth Edition (ICD-9) or ICD-9 clinical modification (ICD-9-CM) code for Dementia/Dementia related (ICD-9: 290.0, 290.10, 290.11, 290.12, 290.13, 290.20, 290.21, 290.3, 290.40, 290.41, 290.42, 290.43, 294.0, 294.8, 294.10, 294.20; ICD-9-CM: 331.11, 331.2, 331.7) and AD (ICD-9-CM: 331.0) in any of four diagnosis fields on outpatient claims or any of five diagnosis fields on inpatients claims. Of these, 398,128 patients were at least 65 years old, and 103,402 were continuously enrolled in the Medicare supplemental database and had continuous health plan enrollment with medical and pharmacy benefits for at least 6 months pre-index period (baseline) and 6 months post-index date. Existing BD diagnostic codes 294.11 and 294.21 were used as a proxy for agitation because ICD-9 diagnostic codes were not available to identify agitation. To identify patients with late-stage disease, patients were flagged with late-stage disease per Fillit et al. 2002 criteria [26]: presence of decubiti (707.00), malnutrition (260, 261, 262, 263.1, 263.2, 263.8, 263.9), and aspiration pneumonia (507.x).

Aigbogun MS, Stellhorn R, Hartry A, Baker RA, Fillit H. Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis. BMC neurology. 2019 Dec 1;19(1):33.

# PheKB



#### Table 1: Comorbidities for Appendicitis (Case Exclusion)

ICD9	Description		
575.0	Acute cholecystitis		
788.0	Right ureteric colic		
633.0	Ectopic pregnancy		
486	Pneumonia		
533.5	Perforated peptic ulcer (without obstruction)		
533.51	Perforated peptic ulcer (with obstruction)		
599.0	Urinary tract infection		
614.2	Salpingitis/		
614.9	pelvic inflammatory disease		
558.9	Gastroenteritis		
560.9	Intestinal obstruction		
590.80	pyelonephritis		
590.10	pyelonephritis (acute pyelonephritis)		
590.00	pyelonephritis (chronic pyelonephritis)		
620.0	Ruptured ovarian follicle		
250.1	Diabetic ketoacidosis (type 2 or unspecified)		
250.11	Diabetic ketoacidosis (type 1; juvenile)		
250.12	Diabetic ketoacidosis (type 2 uncontrolled)		
250.13	Diabetic ketoacidosis (type 1 ; juvenile, uncontrolled)		
577.0	Pancreatitis		
620.2	Torted ovarian cyst		
555.0	Terminal ileitis (small intestine)		
555.1	Terminal ileitis (large intestine)		
555.2	Terminal ileitis(small and large intestine)		
560.0	Intussusception		
277.1	Porphyria		
751.0	Meckel's diverticulitis		
780.96	Preherpetic pain (generalized pain)		
562.11	Colonic/diverticulitis		
543.9	appendicular diverticulitis (diverticula appendicular)		
289.2	Mesenteric adenitis		
924.9	Rectus sheath haematoma (hematoma) (no code for rectus sheath)		

https://phekb.org





http://projectphema.org

ATLAS	PheK8-Dementia-PJ	🗈 🗙 🖆 🗞 🗎
🖶 Home	Definition 🕐 Concept Sets Generation Reporting Export Messages 3	
Data Sources	enter a cohort definition description here	
<b>Q</b> Search	Cohort Entry Events	9
😭 Concept Sets	Events having any of the following criteria:	+ Add Initial Event -
😁 Cohort Definitions	a visit occurrence of Any Visit 👻	Delete Criteria
🗠 Characterizations	with continuous observation of at least $0$ v days before and $0$ v days after event index date	
📥 Cohort Pathways	with continuous observation of at least $[0]$ days before and $[0]$ days after event index date Limit initial events to: all events $\checkmark$ per person.	
Incidence Rates	Restrict initial events to: having any of the following criteria:	+ Add criteria to group
💄 Profiles		
රැූ Estimation	with at least v 5 v using all occurrences of: a visit occurrence of Any Visit v	Delete Criteria
😵 Prediction	having any V of the following criteria:	
🛢 Jobs	Delete Criteria	
<b>©</b> Configuration	with <u>at least</u> <u>i</u> <u>using all</u> occurrences of:	
🗩 Feedback	a drug exposure of PheKB Dementia meds - + Add attribute+	
	× allow events from outside observation period	
	or with at least v 1 v using all occurrences of:	
	a condition occurrence of PheKB Dementia Dx -	
	where event starts between 0 V days Before V and All V days After V index start date add additional constraint	
	□ restrict to the same visit occurrence	
	allow events from outside observation period	
Apache 2.0	where event starts between 0 v days Before v and All v days After v index start date add additional constraint	
open source software provided by	restrict to the same visit occurrence     allow events from outside observation period	
OHDSI	Limit initial events to: all events v per person.	
<u>join the journey</u>	Remove initial event restriction	

http://www.ohdsi.org

Network • • • • Request       • • • • • • • • • • • • • • • • • • •	PopMedNet Home Requests I	Profile Resources Reports Network	k	Contact Us	Lo
Request       Image: Compose queries that target populations using 3, 4, and 5 digit ICD-9 diagnosis codes that produce counts stratified by code age, race, sex, and priod.         Name       Mormal       Die Date       Project         Name       Mormal       Mormal       Mormal         Description       Recurst of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period, 5 year age group, sex, and race         Activity       Tak         Run Mode       Run mediately After I Click "Submit"         Schedule to Run Later       Rece Selector         ICD 9 Codes       230 [Add Codes]         230 [Add Codes]       Make and fem         Age Range       Sea         IS as Sea       Male and fem         IS as Sea       Male and fem         Is ass       Male and fem         Variable       Sea         IS DataMart Routing       Operations         Prese schedul bates to which this query will be sent       Submit         Variable       Submit					
ICD-9 Diagnosis         Compose queries that target populations using 3, 4, and 5 digit ICD-9 diagnosis codes that produce counts stratified by code age, race, sex, and period.         Nime Priority Wormal Decode         Name Collabetes Query Wormal Decode       Project         Mirk Collabetes Query Wormal Decode       Project         Mirk Collabetes Query Wormal Decode       Project         Beschild       Mini Sentine [x]         Beschild       Tark         Beschild       Priority Wormal Decode         Beschild       Name Control of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period. Syear age group, sex, and race         Activity Tark       Tark         Beschild       Tark         Beschild       Run Innmediately After I Click "Submit"         Schedule to Run Later       Voriable         ICD 9 Codes       250 Add Codes         Observation Period Range       Race Selector         State Freid       Gad Period         Min Max       Sec         Back or African American       Res         Min Max       Sec         Back or African American       Sex         Native Hawaiian or Other Pacific       Sex         V Andeand Fem       Submit	Network @ 🌅 Requests @ 🔯 NIH PoC	Diabetes Wuery (Copy)			
Compose queries that target populations using 3, 4, and 5 digit ICD-9 diagnosis codes that produce counts stratified by code age, race, sex, and period. Name Priority Nermal Priority Normal Priority Normal Priority Normal Priority Project Mini-Sentine Returns counts of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period. 5 year age group, sex, and race Activity Tak Returns counts of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period. 5 year age group, sex, and race Activity Tak Returns counts of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period. 5 year age group, sex, and race Activity Tak Returns counts of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period. 5 year age group, sex, and race Activity Returns counts of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period. 5 year age group, sex, and race Returns counts of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period. 5 year age group, sex, and race Returns counts of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period. 5 year age group, sex, and race Returns counts of male and fem Returns counts of the return counts of the retu	Request				2
Compose queries that target populations using 3, 4, and 5 digit ICD-9 diagnosis codes that produce counts stratified by code age, race, sex, and period. Name Priority Nermal Priority Normal Priority Normal Priority Normal Priority Project Mini-Sentine Returns counts of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period. 5 year age group, sex, and race Activity Tak Returns counts of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period. 5 year age group, sex, and race Activity Tak Returns counts of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period. 5 year age group, sex, and race Activity Tak Returns counts of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period. 5 year age group, sex, and race Activity Returns counts of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period. 5 year age group, sex, and race Returns counts of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period. 5 year age group, sex, and race Returns counts of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period. 5 year age group, sex, and race Returns counts of male and fem Returns counts of the return counts of the retu					
Name Project     Name Project   Project   Mini-Sentine [x]   Project   Name Project   Objection Project   Mini-Sentine [x]   Project Project   Projec	ICD-9 Diagnosis				
Name       Project       Normal       Due Date       Project         NH Po C Dubectes Query       Normal       Image: Construction of the construction of t		ing 3, 4, and 5 digit ICD-9 diagnosis codes th	at produce counts stratified	by code age, race, sex, and	
Num Hoc Dubetes Query Normal   Description   Returns counts of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period, 5 year age group, sex, and race   Activity Task   Run Mode   B Run Immediately After 1 Click "Submit"   Schedule to Run Later   ICD 9 Codes   250   Add Codes     Observation Period Range   Submit   Discretation Period Range   Submit   Min Max   12   Min Max   13   95   Male and Fem   White     Discretation to which this query will be sent     Y + DataMart	period.				
Description         Returns counts of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period, 5 year age group, sex, and race         Achilty       Tark         Run Mode       Image: Stratified by 3 digit ICD9 code, monthly period, 5 year age group, sex, and race         Run Mode       Image: Stratified by 3 digit ICD9 code, monthly period, 5 year age group, sex, and race         Run Mode       Image: Stratified by 3 digit ICD9 code, monthly period, 5 year age group, sex, and race         ICD 9 Codes       250 Add Codes         Observation Period Range       Image: Stratified by 3 digit ICD9 code, monthly period, 5 year age group, sex, and race         Age Range       Codes         250 Add Codes       Image: Stratified by 3 digit ICD9 code, monthly period, 5 year age group, sex, and race         Age Range       Image: Stratified by 3 digit ICD9 code, monthly period, 5 year age group, sex, and race         Image: Stratified by After I Click "Submit"       Image: Stratified by 3 digit ICD9 code         Image: Stratified by 3 digit ICD9 code       Image: Stratified by 3 digit ICD9 code       Image: Stratified by 3 digit ICD9 code         Image: Stratified by 3 digit ICD9 code       Image: Stratified by 3 digit ICD9 code       Image: Stratified by 3 digit ICD9 code       Image: Stratified by 3 digit ICD9 code         Image: Stratified by 3 digit ICD9 code       Image: Stratified by 3 digit ICD9 code       Image: Stratified by 3					
Returns counts of male and female patients with diabetes between 18 and 65 stratified by 3 digit ICD9 code, monthly period, 5 year age group, sex, and race   Activity Tark   Run Mode Run Immediately After 1 Click "Submit"   Schedule to Run Later   ICD 9 Codes   250 Add Codes   Period Range   Start Period Range   Start Period Codes   250 Add Codes   Period Monthly Period Range   V Race   Vunknown	NIH PoC Diabetes Query Normal		Min	-Sentinel [x]	
Activity       Taik         Run Mode <ul> <li>Run Immediately After I Click "Submit"</li> <li>Schedule to Run Later</li> </ul> ICD 9 Codes       250         250       Add Codes         2101/2000       12/31/2010         Q       American Indian or Alaska Native         Q       Age         3       Black or African American         Q       Age         Q       Race         Black or African American         Q       Race         Center       Q         Q       Race         Center       Q         DataMart Routing       Operations Center					
Run Mode       Run Immediately After I Click "Submit"         Schedule to Run Later         ICD 9 Codes         250 Add Codes         250 Add Codes         UD 9 Codes         250 Add Codes         Variable Setting         Varitive Hawaiian or Other Pacific </td <td>Returns counts of male and female patients with d</td> <td>iabetes between 18 and 65 stratified by 3 digit ICD9</td> <td>code, monthly period, 5 year age</td> <td>e group, sex, and race</td> <td></td>	Returns counts of male and female patients with d	iabetes between 18 and 65 stratified by 3 digit ICD9	code, monthly period, 5 year age	e group, sex, and race	
Run Mode         Run Immediately After I Click "Submit"         Schedule to Run Later         ICD 9 Codes         250 Add Codes         Observation Period Range         Start Period         Maxeervrvn         D/D1/20200 12/31/2010         Age Range         Gender         Mine         Sex         B = 5         Make and Fem •         Variable Setting         Variable Seting         Variable Setting<				6	
Run Immediately After I Click "Submit"         Schedule to Run Later         ICD 9 Codes         250 Add Codes         Observation Period Range         Start Period         Start Period         Dutation         Age Range         Sea         Win Max         Sea         Waite and Fem         White					
Run Immediately After I Click "Submit" Schedule to Run Later     ICD 9 Codes 250 Add Codes     250 Add Codes     Observation Period Range Start Period Start Period Codes 200/2000 12/31/2010     Age Range Gender Sex Male and Fem *     White    Please select DataMarts to which this query will be sent					
Schedule to Run Later         ICD 9 Codes         250 Add Codes         Observation Period Range         Start Period         Start Period         DotalMart Routing         Please select DataMarts to which this query will be sent         Image Start         Operations Center	Run Mode				
ICD 9 Codes         250 Add Codes         Observation Period Range         Start Period         Start Period         Diverservery         Min         Min         Sex         Black or African American         Discort African American	Run Immediately After I Click "Submit"				
250 Add Codes         Observation Period Range         Start Period       End Period         JU0/2000 12/31/2010       Image: Construction Indian or Alaska Native         Image: Construction Period       Image: Construction Indian or Alaska Native         Image: Construction Period       Image: Construction Indian or Alaska Native         Image: Construction Period       Image: Construction Indian or Alaska Native         Image: Construction Period       Image: Construction Indian or Alaska Native         Image: Construction Period       Image: Construction Indian or Alaska Native         Image: Construction Period       Image: Construction Indian or Alaska Native         Image: Construction Period       Image: Construction Indian or Alaska Native         Image: Construction Period       Image: Construction Indian or Alaska Native         Image: Construction Period       Image: Construction Indian or Alaska Native         Image: Construction Period       Image: Construction Indian or Alaska Native         Image: Construction Period       Image: Construction Indian or Alaska Native         Image: Construction Period       Image: Construction Indian or Alaska Native         Image: Construction Period       Image: Construction Indian or Alaska Native         Image: Construction Period       Image: Construction Indian or Alaska Native         Image: Construction Period					
250 Add Codes         Observation Period Range Start Period End Period Makrearren D1/01/2000 12/31/2010       Race Selector         V Race Min Max 18 65       V Race Sex Male and Fem •       V Race American Indian or Alaska Native V Asian Black or African American V Native Hawaiian or Other Pacific Islander (NHOPI) V White       Race Sex V Race Center         DataMart Routing       V         Please select DataMarts to which this query will be sent       Submit         Sp DataMart V DataMart       Operations Center					
Observation Period Range       Race Selector         Start Period       End Period         Maxeevrmg       Wateevrmg         D1/01/2000       12/31/2010         Ø       American Indian or Alaska Native         Ø       American Indian or Alaska Native         Ø       Asian         Ø       Asian         Ø       Black or African American         Ø       Native Hawaiian or Other Pacific         Islander (NHOPI)       Ø         Ø       White	ICD 9 Codes				
Start Period IMARENYNY D1/01/2000       Image: Start period Image:	250 Add Codes				
Start Period IMMEEVYNY D1/01/2000       Immeevyny D2/231/2010       Immeevyny D1/01/2000       Immeevyny D2/231/2010       Immeev					
Start Period IMMEEVYNY D1/01/2000       Immeevyny D2/231/2010       Immeevyny D1/01/2000       Immeevyny D2/231/2010       Immeev		P. C.L.			
DataMart Routing         Place Serving         Directions         Age Range         Min         Sex         Black or African American         Black or African American         Black or African American         Native Hawaiian or Other Pacific         Islander (NHOPI)         White		Race Selector	Report Selector		_
Age Range       Gender         Min       Max         18       65         Male and Fem       Black or African American         Native Hawaiian or Other Pacific       Islander (NHOPI)         White       Center		Race	Variable S		
Age Range       Gender         Min       Max         18       65         Wale and Fem       Black or African American         Wale and Fem       Native Hawailan or Other Pacific         Islander (NHOPI)       Race         White       Center         DataMart Routing       Please select DataMarts to which this query will be sent         V       DataMart         Operations Center       Save	01/01/2000 12/31/2010	🗹 Unknown	ICD-9	3 Digit	
Min       Max         18       65         Male and Fem       Image         Image       Stream		American Indian or Alaska Native	Period	Monthly	
18       65       Male and Fem •       Image: Black or African American         Image: Native Hawaiian or Other Pacific Islander (NHOPI)       Image: Race         Image: White       Image: Center         Image: DataMart Routing       Image: Center         Please select DataMarts to which this query will be sent       Submit         Image: Please select DataMart Organization       Submit         Image: Sep DataMart Operations Center       Save	Age Range Gender	🕅 Asian	🗵 Age	5 Year Age Group	
Native Hawaiian or Other Pacific Islander (NHOPI)     White  DataMart Routing  Please select DataMarts to which this query will be sent      Submit     Submit     Save      Save		Black or African American	Sex		
Islander (NHOPI)     Center       White     Center	18 65 Male and Fem		Race		
White       DataMart Routing       Please select DataMarts to which this query will be sent       Image: Constraint organization					-
DataMart Routing     [       Please select DataMarts to which this query will be sent     [       Image: Control of the sent in the		V White	Center		_
Please select DataMarts to which this query will be sent     Submit       Image: Comparison of the sent of the sen		as mine	1		
V     DataMarts to which this query will be sent       V     DataMart     Organization       ESP DataMart     Operations Center		V White			-
Please select DataMarts to which this query will be sent     Submit       Image: Comparison of the sent of the sen					
Please select DataMarts to which this query will be sent     Submit       Image: Comparization     Save       Image: Comparization     Save	DetaMest Deutine				
Image: Constraint of the second sec	J DataMart Kouting				l
Image: Constraint of the second sec	Please select DataMarts to which this overy will be	sent	)		
Save Save			Submit		
ESP DataMart     Operations Center	🖉 🔺 DataMart	Organization			
Image: Wight of the second s		Operations Center	Save		
En lass balantars operations center	ESP DataMart				
		Operations Contes	CODV		
		Operations Center	Сору		

https://www.popmednet.org/



https://www.i2b2.org/

### **Computable Phenotype Instantiations**

```
"ConceptSets": [
 "id": 0.
 "name": "PheKB Dementia Dx"
 "expression": {
   "items": [
    "concept": {
     "CONCEPT_ID": 374326,
     "CONCEPT_NAME": "Arteriosclerotic dementia with depression",
     "STANDARD_CONCEPT": "S",
     "STANDARD CONCEPT CAPTION": "Standard".
     "INVALID_REASON": "V",
     "INVALID_REASON_CAPTION": "Valid",
     "CONCEPT_CODE": "191466007",
     "DOMAIN_ID": "Condition",
     "VOCABULARY ID": "SNOMED"
     "CONCEPT_CLASS_ID": "Clinical Finding"
    3.
     "includeDescendants": true
     "concept": {
     "CONCEPT ID": 4100252.
     "CONCEPT_NAME": "Arteriosclerotic dementia with paranoia",
     "STANDARD CONCEPT": "S".
     "STANDARD_CONCEPT_CAPTION": "Standard",
     "INVALID_REASON": "V",
     "INVALID_REASON_CAPTION": "Valid",
     "CONCEPT_CODE": "191465006",
     "DOMAIN_ID": "Condition",
     "VOCABULARY ID": "SNOMED".
     "CONCEPT_CLASS_ID": "Clinical Finding"
     "includeDescendants": true
     "concept": {
      "CONCEPT_ID": 376094,
      "CONCEPT NAME": "Arteriosclerotic dementia with delirium"
```

with t as ( select f.patient num from synpuf omop.dbo.measurement view f where f.concept cd IN (select concept cd from synpuf omop.dbo.concept dimension where concept path LIKE '\i2b2\Diagnoses\Endocrine disorders (240-259)\Other endocrine gland diseases (250-259)\(250) Diabetes mellitus\%') group by f.patient num insert into #global\_temp\_table (patient\_num, panel\_count) select t.patient num, 0 as panel count from t <panel> <item> <item\_name>Diabetes mellitus</item\_name> <item key>\\OMOP\_COND\i2b2\Diagnoses\Endocrine disorders (240-259)\Other endocrine gland diseases (250-259)\(250) Diabetes mellitus\ </item key> </item> </panel> <panel> <item> <item name>Female</item name> <item\_key>\\OMOP\_DEMO\OMOP Demographics\Gender\(8532)Female\</item\_key> </item> </panel> <panel> <item> <item name>Black or African American</item name> <item\_key>\\OMOP\_DEMO\OMOP Demographics\Race\(8516)Black or African American\</item\_key> </item> </panel>

### All the above examples are Research Data Models

#### **Research Data Models**

- Population level
- Designed to support analytics
- Handful of models
- Adoption varies nationally and internationally
  - Driven by funding and collaborations
  - Dominated by academic medical centers
- In the United States, no mandate regarding research data models

#### **Transactional Data Models**

- Patient level
- Designed to support clinical operations
- Hundreds of data models (EHRs + HL7 v2/3/FHIR)
- Wide array of local code systems
- Proprietary/bespoke formats limit utility for queries beyond a single site
- In the US, new regulatory policy has emerged with significant implications for transactional data models

# 21st Century Cures Act

Signed December 13, 2016 Office of the National Coordinator on Health IT (ONC) published CURES Act Final Rule May 1, 2020

### The Big Stuff

- US Core Data for Interoperability (USCDI)
  - Establishes a set of data classes and elements that all Certified Health IT software must be able to export (by 2022/2023)
  - Specifies terminology(ies) for each data class
  - Specifies a process for updating the above based on stakeholder needs and IT burden

https://www.federalregister.gov/documents/2020/05/01/2020-07419/21st-century-cures-act-interoperabilityinformation-blocking-and-the-onc-health-it-certification



and

Information about a condition, diagnosis, or other event, situation, issue, or clinical concept that is documented.

Problems

Data Element		Applicable Standards(s)
<u>Problems</u>	>	SNOMED International, Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT®) U.S. Edition, September 2019 Release
Tests	>	<ul> <li>Logical Observation Identifiers Names and Codes (LOINC®) Database version 2.67</li> </ul>
Medications	>	<ul> <li>RxNorm, January 6, 2020 Full Release Update</li> </ul>

🚰 🕮 🖂					
Represents harmful or undesirable physi	ological respon	ise associated with exposure to a substance.			
llı, uscdi vi					
Data Element		Applicable Standards(s)			
Substance (Drug Class)	>	<ul> <li>SNOMED International, Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT®) U.S. Edition, September 2019 Release</li> </ul>			
Substance (Medication)	>	<ul> <li>RxNorm, January 6, 2020 Full Release Update</li> </ul>			
<u>Reaction</u>	>	<ul> <li>SNOMED International, Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT®) U.S. Edition, September 2019 Release</li> </ul>			

Patient Demographics		<b>-</b> 🖱 🖂
llı, USCDI V1		
Data Element	Applicable Standards(s)	
Birth Sex	Birth sex must be coded in accordance with HL7 Version 3 (V3) Standard, Value Sets for AdministrativeGender and NullFlavor (https://www.healthit.gov/sites/default/files/170299_f_29_hl7_v3_agender_and_nullflavor.pdf) attributed as follows: 1. Male. M 2. Female. F	
	3. Unknown. nullFlavor UNK	
Comment		

**a** 🔁 🖂

#### Clinical Notes

Composed of both structured (i.e. obtained via pick-list and/or check the box) and unstructured (free text) data. A clinical note may include the history, Review of Systems (ROS), physical data, assessment, diagnosis, plan of care and evaluation of plan, patient teaching and other relevant data points.

IIIi USCDI V1	
Data Element	Applicable Standards(s)
Consultation Note	<ul> <li>Consult Note (LOINC® code 11488-4)</li> </ul>
Discharge Summary Note	> Discharge Summary (LOINC® code 18842-5)
History & Physical	<ul> <li>History and Physical Note (LOINC® code 34117-2)</li> </ul>
Imaging Narrative	<ul> <li>Diagnostic Imaging Study (LOINC® code 18748-4)</li> </ul>
Laboratory Report Narrative	>
Pathology Report Narrative	>
Procedure Note	<ul> <li>Procedure Note (LOINC® code 28570-0)</li> </ul>
Progress Note	<ul> <li>Progress Note (LOINC® code 11506-3)</li> </ul>

### Cures Act and FHIR

- USCDI specifies only content, not the means of transmission
- In terms of format, ONC specifies that API-based exchange of health data should be done via FHIR Release 4
- These two elements (USCDI and FHIR R4) are rolled together through the FHIR US Core profiles
  - Define which FHIR resources and elements satisfy the USCDI exchange requirements

USCDI v1 Summary of Data Classes and Elements	Data US Core Profile	FHIR Resource
Assessment and Plan of Treatment	US Core CarePlan Profile	CarePlan
Care Team Members	US Core CareTeam Profile	CareTeam
Clinical Notes:		
Consultation Note	US Core DocumentReference Profile	DocumentReference
Discharge	US Core DocumentReference Profile	DocumentReference
Summary Note	US Core DocumentReference Profile	DocumentReference
History & Physical	US Core DocumentReference Profile, US Core DiagnosticReport Profile for Report and Note exchange	DocumentReference, DiagnosticReport
Imaging Narrative	US Core DocumentReference Profile, US Core DiagnosticReport Profile for Report and Note exchange	DocumentReference, DiagnosticReport
Laboratory Report Narrative	US Core DocumentReference Profile, US Core DiagnosticReport Profile for Report and Note exchange	DocumentReference, DiagnosticReport
Pathology Report Narrative	US Core DocumentReference Profile, US Core DiagnosticReport Profile for Report and Note exchange	DocumentReference, DiagnosticReport
Procedure Note	US Core DocumentReference Profile, US Core DiagnosticReport Profile for Report and Note exchange	DocumentReference, DiagnosticReport
Progress Note	US Core DocumentReference Profile	DocumentReference
Consultation Note	US Core DocumentReference Profile	DocumentReference
Goals:		
Patient Goals	US Core Goal Profile	Goal
Health Concerns	US Core Condition Profile	Condition
Immunizations	US Core Immunization Profile	Immunization
Laboratory:		
Tests	US Core Laboratory Result Observation Profile, US Core DiagnosticReport Profile for Laboratory Results Reporting	Observation, DiagnosticReport
Values/Results	US Core Laboratory Result Observation Profile, US Core DiagnosticReport Profile for Laboratory Results Reporting	Observation, DiagnosticReport
Medications:		
Medications	US Core Medication Profile, , US Core Medication Request Profile	Medication, MedicationStatement
Medication Allergies	US Core Allergies Profile	AllergyIntolerance
Patient Demographics:		
First Name	US Core Patient Profile	Patient.name.given
Last Name	US Core Patient Profile	Patient.name.family
Previous Name	US Core Patient Profile	Patient.name
Middle Name (including middle initial)	US Core Patient Profile	Patient.name.given
Suffix	US Core Patient Profile	Patient.name.suffix
Birth Sex	US Core Patient Profile	US Core Birth Sex Extension
Date of Birth	US Core Patient Profile	Patient.birthDate
Race	US Core Patient Profile	US Core Race Extension

https://www.hl7.org/fhir/us/core/general-guidance.html

#### USCDI<->FHIR US Core

#### 3.3.1 StructureDefinition-us-core-observation-lab

Laboratory results are grouped and summarized using the DiagnosticReport are resource which reference Observation are resources. Each Observation resource represents an individual laboratory test and result value, a "nested" panel (such as a microbial susceptibility panel) which references other observations, or rarely a laboratory test with component result values. This profile sets minimum expectations for the Observation resource resource to record, search, and fetch laboratory test results associated with a patient. It identifies which core elements, extensions, vocabularies and value sets SHALL be present in the resource when using this profile.

#### Example Usage Scenarios:

The following are example usage scenarios for the US Core-Results profile:

- · Query for lab results belonging to a Patient
- · Record or update lab results belonging to a Patient

#### 3.3.1.1 Mandatory and Must Support Data Elements

The following data-elements are mandatory (i.e data MUST be present) or must be supported if the data is present in the sending system (Must Support definition). They are presented below in a simple human-readable explanation. Profile specific guidance and examples are provided as well. The Formal Profile Definition below provides the formal summary, definitions, and terminology requirements.

#### Each Observation must have:

1. a status

- 2. a category code of 'laboratory'
- 3. a LOINC C code, if available, which tells you what is being measured

4. a patient

#### Each Observation must support:

- 1. a time indicating when the measurement was taken
- 2. a result value or a reason why the data is absent
  - if the result value is a numeric quantity, a standard UCUM d unit

#### Profile specific implementation guidance:

- Additional codes that translate or map to the Observation code or category codes are allowed. For example:
  - providing both a local code and LOINC code
  - providing a more specific category codes such as 'chemistry', SNOMED CT I<sup>™</sup> concept, or system specific codes in addition to the 'laboratory' category code.

#### FHIR US Core Laboratory Example

```
"status" : "final",
"category" : [
  {
    "coding" : [
     {
        "system" : "http://terminology.hl7.org/CodeSystem/observation-category",
        "code" : "laboratory",
       "display" : "Laboratory"
     3
   ],
    "text" : "Laboratory"
  }
],
"code" : {
  "coding" : [
   {
      "system" : "http://loinc.org",
      "code" : "1975-2",
      "display" : "Bilirub SerPl-mCnc"
   }
  ],
  "text" : "Bilirub SerPl-mCnc"
},
 "subject" : {
  "reference" : "Patient/example",
  "display" : "Amy Shaw"
},
"effectiveDateTime" : "2005-07-07",
"valueQuantity" : {
  "value" : 8.6,
 "unit" : "mg/dL",
"system" : "http://unitsofmeasure.org"
},
"referenceRange" : [
  {
   "low" : {
     "value" : 2.0,
     "unit" : "mg/dL",
"system" : "http://unitsofmeasure.org",
     "code" : "mg/dL"
    },
    "high" : {
     "value" : 7.0,
     "unit" : "mg/dL",
     "system" : "http://unitsofmeasure.org",
"code" : "mg/dL"
   },
    "appliesTo" : [
     {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/referencerange-meaning",
            "code" : "normal",
            "display" : "Normal Range"
          }
       ],
        "text" : "Normal Range"
      }
   1
```

### **Population Level Data**

- Cures Act mandates the support for both patient and population-level data export
- Does not specify the format for population-level export, but does mandate adoption of the "FHIR Bulk Data Access" (aka BulkFHIR, aka FlatFHIR) group-export functionality

# Back to Phenotyping



### What makes a phenotype portable?

- Uses data types that can be found across systems
- Includes codes that can be found across systems
- Uses logic that can be applied across systems

What makes a phenotype portable?

- Uses data types that can be found across systems
- Includes codes that can be found across systems
- Uses logic that can be applied across systems

### Data Types in Common Models



https://bridgmodel.nci.nih.gov/ https://cbiit.github.io/bridg-model/HTML/BRIDG5.3.1/

### Data Types in Common Models

#### **Common Data Model Harmonization**

- Patient Centered Outcome Research Network (PCORNet) Common Data Model (CDM)
- Informatics for Integration Biology and Bedside (i2b2) model
- Observational Medical Outcomes Partnership (OMOP) model
- Federal Drug Administration's Sentinel model





National Library of Medicine



National Center for Advancing Translational Sciences

1	SENTINEL ID	PCORNet ID	PCORNet v4 ID	i2b2 ID	OMOP ID	CDMH CONCEPTUAL MAPPING	Tagged BRIDG Class Name	Tagged BRIDG Attribute Name
								1
88								
	4.3.PROCEDURE.0	05.PROC.0	05.PROC.0	PROC.0	PROCEDURE_OCCURRENCE.0	PerformedProcedure	PerformedProcedure	
89		05.PROC.01	05.PROC.01		PROCEDURE_OCCURRENCE.1	PerformedProcedure.identifier(DSET <id>).item(ID).identifier</id>	Activity	identifier
90								
	4.3.PROCEDURE.1	05.PROC.02	05.PROC.02		PROCEDURE_OCCURRENCE.2	PerformedProcedure > Subject.identifier(ID).identifier	Subject	identifier
91								
91	4.3.PROCEDURE.2	05.PROC.03	05.PROC.03		PROCEDURE OCCURRENCE.10	PerformedProcedure > PerformedCompositionRelationship > PerformedEncounter.identifier.item(ID).identifier	Activity	identifier
	4.0.1 NOCEDONE.2	05.1100.05	05.PR00.05		PROCEDORE_OCCORRENCE.ID	PerformedProcedure > PerformedCompositionRelationship >	Activity	literative
92	4.3.PROCEDURE.3	05.PROC.05	05.PROC.05			PerformedEncounter.dateRange(IVL <ts.datetime>).low</ts.datetime>	PerformedActivity	dateRange
93								
	4.3.PROCEDURE.4	05.PROC.06	05.PROC.06		PROCEDURE_OCCURRENCE.9	PerformedProcedure > Performer > HealthcareProvider.identifier(DSET <id>).item(ID).identifier</id>	HealthcareProvider	identifier
94								
						PerformedProcedure > PerformedCompositionRelationship > PerformedEncounter >		
	4.3.PROCEDURE.5	05.PROC.04	05.PROC.04			DefinedSubjectActivityGroup.nameCode	DefinedActivity	nameCode
95		05.PROC.07	05.PROC.07		PROCEDURE_OCCURRENCE.4	PerformedProcedure.dateRange(IVL <ts.datetime>).high</ts.datetime>	PerformedActivity	dateRange
96							and the state	1.1
				PROC.4	PROCEDURE_OCCURRENCE.5	PerformedProcedure.dateRange(IVL <ts.datetime>).high</ts.datetime>	PerformedActivity	dateRange

https://www.healthit.gov/topic/scientific-initiatives/pcor/common-data-model-harmonization-cdm

### CDMs to FHIR US core

**OMOP Data Element FHIR Data Element** FHIR Resource/Profile/Extension Table : Person person\_id Patient.identifier us-core-patient provider\_id Patient.generalPractitioner Patient care\_site\_id BodySite.patient BodySite gender concept id Patient.gender us-core-patient year\_of\_birth Patient.birthDate us-core-patient month\_of\_birth Patient.birthDate us-core-patient day\_of\_birth Patient.birthDate us-core-patient birth\_datetime Patient.birthDate us-core-patient race\_concept\_id Patient.extension: us-core-race us-core-patient ethnicity\_concept\_id Patient.extension: us-core-ethnicity us-core-patient location\_id Patient.address Patient Table : VISIT\_OCCURRENCE visit\_occurence\_id Encounter.id us-core-encounter care\_site\_id Encounter.location.location.identifier us-core-encounter, us-core-location admitting\_source\_concept\_id Encounter.hospitalization.admitSource or Encounter.hospitalization.origin(location).type us-core-encounter, us-core-location discharge\_to\_concept\_id Encounter.location.location.type us-core-encounter,us-core-location preceding\_visit\_occurence Encounter.partOf us-core-encounter person\_id Encounter.subject us-core-encounter visit\_concept\_id Encounter.type us-core-encounter visit\_start\_date Encounter.period us-core-encounter visit\_start\_datetime Encounter.period us-core-encounter visit\_end\_date Encounter.period us-core-encounter visit\_end\_datetime Encounter.period us-core-encounter visit\_type\_concept\_id Encounter.extension (Proposed Name: source-data-type : CodeableConcept) us-core-encounter Table : CARE SITE care\_site\_id Location.id us-core-location care\_site\_name Location.name us-core-location place\_of\_service\_concept\_id us-core-location Location.type location\_id Location.address us-core-location Table : CONDITION\_OCCURRENCE condition\_occurrence\_id Condition.id us-core-condition provider\_id Condition.asserter us-core-condition visit\_occurrence\_id Condition encounter us-core-condition condition\_status\_concept\_id Condition.clinicalStatus us-core-condition person id Condition.subject us-core-condition condition\_concept\_id Condition.code us-core-condition

http://build.fhir.org/ig/HL7/cdmh/profiles.html

PCORNet OMOP i2b2 Sentinel Playing the Classics vs Skating to the Puck

- Ensuring the portability of phenotypes at present still requires focusing on the classic data types
  - Conditions
  - Medications
  - Procedures
  - Observations / Labs (presence of)
  - Encounters
- But adoption of USCDI and FHIR Core expands the potential to incorporate elements such as vital signs, laboratory results, and clinical notes from EHR sources

### What makes a phenotype portable?

- Uses data types that can be found across systems
- Includes codes that can be found across systems
- Uses logic that can be applied across systems

How do we know what codes are in what system?

- New cohort characterization tools greatly expand our ability to understand the availability and impact of code selection
- Specifically we are seeking to understand what codes are actually used in cohort generation and how that differs from site to site
### Spotlight: OHDSI Characterization Tools

Older OHDSI tools let you look at counts of codes for a given dataset or a generated cohort

Column v	isibility Copy CSV Show 15 T entries	Filter	hypertension	
11 (11 (11 (11 (11 (11 (11 (11 (11 (11	to 15 of 47 entries om 15,907 total entries)	Prev	ious 1 2 3	4 Nex
Concept Id	Name	Person Count	Prevalence	Records per person
320128	Essential hypertension	17,814,076	12.30%	5.8
312648	Benign essential hypertension	11,014,877	7.61%	4.3
317898	Malignant essential hypertension	1,021,441	0.70%	2.2
381290	Ocular hypertension	521,264	0.36%	2.4
441922	Transient hypertension of pregnancy	209,317	0.14%	2.4
44782429	Chronic kidney disease due to hypertension	170,534	0.12%	3.6
137940	Transient hypertension of pregnancy - delivered	153,806	0.11%	1.0
321080	Hypertension complicating pregnancy, childbirth and the puerperium	148,728	0.10%	2,1
314423	Benign essential hypertension complicating pregnancy, childbirth and the puerperium - not delivered $% \left( {{{\left[ {{{\rm{D}}_{\rm{T}}} \right]}}} \right)$	132,245	0.09%	3.9
44782690	Chronic kidney disease stage 5 due to hypertension	119,375	0.08%	5,2
44783618	Heritable pulmonary arterial hypertension	104,737	0.07%	3.6
319826	Secondary hypertension	96,356	0.07%	2.1
4167493	Pregnancy-induced hypertension	91,675	0.06%	2.6
321074	Pre-existing hypertension complicating pregnancy, childbirth and puerperium	74,311	0.05%	2.9
192680	Portal hypertension	71.240	0.05%	3.1

https://ohdsi.github.io/TheBookOfOhdsi/Characterization.html

#### Spotlight: OHDSI Characterization Tools

Cohort Diagnostics					
Cohort Counts	•	Show 25 v entries		Search:	
Incidence Rate	•	Concept ID 🔶 Name	🕴 CUIMC Count 🖗	IQVIA_OpenClaims Count 🕴	VA-OMOP Count
		700360 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	5,297	49,357	2,946
Time Distributions	0	706163 SARS coronavirus 2 RNA [Presence] in Respiratory specimen by NAA with probe detection	4,925		
Included (Source) Concepts		723479 SARS coronavirus 2 IgG+IgM Ab [Presence] in Serum or Plasma by Immunoassay	1,207		
	<b>.</b>	723474 SARS coronavirus 2 IgG Ab [Presence] in Serum or Plasma by Immunoassay	250		
Orphan (Source) Concepts	0	723475 SARS coronavirus 2 IgM Ab [Presence] in Serum or Plasma by Immunoassay	211		
Index Event Breakdown	-	706180 SARS coronavirus 2 IgM Ab [Presence] in Serum or Plasma by Rapid immunoassay	18		
Index Event Breakdown	•	706181 SARS coronavirus 2 lgG Ab [Presence] in Serum or Plasma by Rapid immunoassay	18		
Database information		723473 SARS coronavirus 2 IgA Ab [Presence] in Serum or Plasma by Immunoassay	5		
		706163 SARS-CoV-2 (COVID19) RNA [Presence] in Respiratory specimen by NAA with probe detection			11,631
Database		723463 SARS-CoV-2 (COVID19) RNA [Presence] in Serum or Plasma by NAA with probe detection			207
		40218804 Testing for SARS-CoV-2 in non-CDC laboratory		20,776	361
		40218805 Testing for SARS-CoV-2 in CDC laboratory		2,107	35
HM_Hospitales		Showing 1 to 12 of 12 entries		Previo	ous 1 Next

IQVIA\_OpenClaims

optum\_ehr\_covid\_v1239

CDM\_Premier\_COVID\_v1240

prod\_dager

prod\_lpdfr

- SIDIAP
- STARR-OMOR
- cdm\_health\_verity\_v1282\_2
- CPRD\_COVID

#### Cohort (Target)

[COVID ID130 V1] Persons 1

Next-gen Cohort Characterization tools provide extensive insight into how codes are used and what codes may be missing

https://data.ohdsi.org/Covid19CharacterizationCharybdisDiagCovid/

#### How are diabetes patients detected at different sites?

Cohort Diagnostics						
Cohort Counts 🚺	Show 25 v entries				Search:	
Incidence Rate	Concept ID 🕴 Name	CUIMC Count	IQVIA_OpenClaims Count	CDM_Premier_COVID_v1240 Count	STARR-OMOP Count	VA-OMOP Count
	4008576 Diabetes mellitus without complication	151,612	36,123,073	12,353	173,530	3,187,347
Time Distributions	4193704 Type 2 diabetes mellitus without complication	71,495	11,857,942	3,468,637	157,718	539,307
Included (Source) Concepts 👔	201826 Type 2 diabetes mellitus	23,472	5,34 <mark>0,043</mark>	2,091,808	49,664	225,819
	443238 Diabetic - poor control	16,591	5,909,580		16,104	191,526
Orphan (Source) Concepts 🛛 👔	443732 Disorder due to type 2 diabetes mellitus	7,711	1,157,108		11,572	84,134
Index Event Breakdown	37016349 Hyperglycemia due to type 2 diabetes mellitus	5,548	2,351,087	806,976	15,128	52,468
	443767 Disorder of eye due to diabetes mellitus	4,797	850,79 <mark>2</mark>	156	7,572	41,687
Database information	442793 Diabetic complication	4,426			16,192	
	192279 Kidney disorder due to diabetes mellitus	3,721			9,506	
Database	443730 Nervous system disorder due to diabetes mellitus	3,210			6 <b>,</b> 58 <mark>0</mark>	
	376683 Nonproliferative diabetic retinopathy	3,039			2,098	
HM_Hospitales	43531578 Chronic kidney disease due to type 2 diabetes mellitus	2,975	373,804	773,614	7,818	12,743
	40482801 Type II diabetes mellitus uncontrolled	2,966	324,067		1,676	21,203
IQVIA_OpenClaims	376112 Diabetic polyneuropathy	2,871			2,866	
optum_ehr_covid_v1239	195771 Secondary diabetes mellitus	2,777	271,912	17,256	6,502	9,255
CDM_Premier_COVID_v1240	380096 Proliferative retinopathy with diabetes mellitus	2,109			3,392	
prod_dager	443731 Renal disorder due to type 2 diabetes mellitus	2,086	211,268	98,204	4,030	6,878
prod_lpdfr SIDIAP	321822 Peripheral vascular disorder due to diabetes mellitus	2,030	513,817	688	1,218	15,305
SIDIAP SIDIAP_H	443734 Ketoacidosis in type 2 diabetes mellitus	1,870			1,540	
STARR-OMOP	443729 Peripheral circulatory disorder associated with type 2 diabetes mellitus	1,426			1,554	
VA-OMOP	376065 Neurological disorder with type 2 diabetes mellitus	1,343			3,016	
cdm_health_verity_v1282_2	4009303 Diabetic ketoacidosis without coma	1,327	269,947	106,100	3,330	2,992
CPRD_COVID	201820 Diabetes mellitus	1,184	286,413	12,501	3,380	3,093
	37017432 Polyneuropathy due to type 2 diabetes mellitus	869	321,942	220,411	2,300	7,215
Cohort (Target)	43530690 Foot ulcer due to type 2 diabetes mellitus	644	112,756	120,028	656	4,461
[COVID ID100 v1] Prevalen 🐱	Showing 1 to 25 of 158 entries			Previous	1 2 3 4 5	6 7 Next

https://data.ohdsi.org/Covid19CharacterizationCharybdisDiagStrata/

#### What codes included in the definition are found?

rt Counts	ource Concepts 🔘 Standar	rd Concepts			
ence Rate 👔	v 25 v entries	u concepts			
e Distributions					Search:
	Subjects 🖗	Concept ID Vocabulary	Code	Name	
luded (Source) Concepts 🛛 👔	378,347	35206882 ICD10CM	E11.9	Type 2 diabetes mellitus without complications	
	54,058	45581353 ICD10CM	E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	
phan (Source) Concepts 🛛 🕕	22,743	45595798 ICD10CM	E11.36	Type 2 diabetes mellitus with diabetic cataract	
lex Event Breakdown 👔	21,435	45557113 ICD10CM	E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	
	7,040	45533021 ICD10CM	E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	
tabase information	6,714	45605401 ICD10CM	E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	
tabase	5,688	35206885 ICD10CM	E13.9	Other specified diabetes mellitus without complications	
	1,814	45533019 ICD10CM	E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	
SIDIAP Y	1,813	45537963 ICD10CM	E13.59	Other specified diabetes mellitus with other circulatory complications	
	1,341	45595799 ICD10CM	E11.69	Type 2 diabetes mellitus with other specified complication	
nort (Target)	1,341	45595799 ICD10CM	E11.69	Type 2 diabetes mellitus with other specified complication	
COVID ID100 v1] Prevalen 🗸	806	45605404 ICD10CM	E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	
	799	45591027 ICD10CM	E11.21	Type 2 diabetes mellitus with diabetic nephropathy	
ncept Set	716	35206881 ICD10CM	E11.8	Type 2 diabetes mellitus with unspecified complications	
Type 2 Diabetes Mellitus 🛛 🗸	716	35206881 ICD10CM	E11.8	Type 2 diabetes mellitus with unspecified complications	
	465	45600636 ICD10CM	E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	
	446	45547624 ICD10CM	E10.69	Type 1 diabetes mellitus with other specified complication	
	392	45581355 ICD10CM	E11.621	Type 2 diabetes mellitus with foot ulcer	
	392	45581355 ICD10CM	E11.621	Type 2 diabetes mellitus with foot ulcer	
	238	45591034 ICD10CM	E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	
	224	45552388 ICD10CM	E13.29	Other specified diabetes mellitus with other diabetic kidney complication	
	214	45547635 ICD10CM	E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	
	207	45605405 ICD10CM	E11.65	Type 2 diabetes mellitus with hyperglycemia	
	207	45605405 ICD10CM	E11.65	Type 2 diabetes mellitus with hyperglycemia	
	192	45566733 ICD10CM	E13.10	Other specified diabetes mellitus with ketoacidosis without coma	

#### What potentially relevant codes were not in the definition?

ts 🕕 Sh	ow 25 🗸 entries					Search:
Rate 👔	Count	Concept ID 🕴 Standard	Vocabulary	¢ Code	🔷 Name	
	96,694	45558215	ICD10CM	024.419	Gestational diabetes mellitus in pregnancy, unspecified control	
ributions 🕕	52,236	4051114 S	SNOMED	160303001	Family history of diabetes mellitus	
ource) Concepts 👔	48,381	4024659 S	SNOMED	11687002	Gestational diabetes mellitus	
	34,075	443412 S	SNOMED	313435000	Type 1 diabetes mellitus without complication	
urce) Concepts 🛛 🕕	34,075	35206879	ICD10CM	E10.9	Type 1 diabetes mellitus without complications	
Breakdown	23,920	45572771	ICD10CM	024.919	Unspecified diabetes mellitus in pregnancy, unspecified trimester	
	11,961	4058243 S	SNOMED	199223000	Diabetes mellitus during pregnancy, childbirth and the puerperium	
nformation	11,159	45533300	ICD10CM	H35.00	Unspecified background retinopathy	
	1,803	318712 S	SNOMED	421365002	Peripheral circulatory disorder due to type 1 diabetes mellitus	
	1,788	45581349	ICD10CM	E10.59	Type 1 diabetes mellitus with other circulatory complications	
~	1,465	201254 S	SNOMED	46635009	Type 1 diabetes mellitus	
	1,440	37201113	ICD10CM	R73.03	Prediabetes	
rget)	1,440	37018196 S	SNOMED	714628002	Prediabetes	
100 v1] Prevalen 🗸	1,246	30968 S	SNOMED	15771004	Diabetes insipidus	
	1,246	35206911	ICD10CM	E23.2	Diabetes insipidus	
:	655	45576438	ICD10CM	E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	
abetes Mellitus 🗸 🗸	655	200687 S	SNOMED	421893009	Renal disorder due to type 1 diabetes mellitus	
	655	42538169 S	SNOMED	739681000	Disorder of eye due to type 1 diabetes mellitus	
	647	45600637	ICD10CM	E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	
	321	35210608	ICD10CM	P70.0	Syndrome of infant of mother with gestational diabetes	
	321	42538560 S	SNOMED	762291006	Syndrome of infant of mother with gestational diabetes	
	282	377821 S	SNOMED	421468001	Disorder of nervous system due to type 1 diabetes mellitus	
	269	45586138	ICD10CM	E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	
	196	45605398	ICD10CM	E10.621	Type 1 diabetes mellitus with foot ulcer	
	133	46269972 S	SNOMED	10995761000119100	History of diabetic foot ulcer	

https://data.ohdsi.org/Covid19CharacterizationCharybdisDiagStrata/

# What about Obesity?

cept ID 🖗 Name	CUIMC Count	IQVIA_OpenClaims Count 🏺	CDM_Premier_COVID_v1240 Count	STARR-OMOP Count	VA-OMOP Count
3025315 Body weight	488,882		341	346,855	2,926,25
3038553 Body mass index (BMI) [Ratio]	485,396			340,567	
3027492 Dry body weight Measured	152,568				
433736 Obesity	106,801	31,355,725	2,209,239	76,399	3,312,89
434005 Morbid obesity	42,115	9,764,068	1,270,926	25,091	249,93
42872398 Maternal obesity complicating pregnancy, childbirth and the puerperium, antepartum	4,890	1,299,918	93,910	3,870	92
439893 Maternal obesity syndrome	3,123	401,402	3,793	641	1,46
3013762 Body weight Measured	3,011				<
4060985 Body mass index 30+ - obesity	2,026	13,374,128	1,486,249	5,525	412,89
438731 Localized adiposity	1,640	239,261	10,621	2,185	9,18
4256640 Body mass index 40+ - severely obese	1,292	3,608 <mark>,905</mark>	972,849	2,459	56,01
0481140 Childhood obesity	688	973,161		4,721	7
3023166 Body weight Stated	201			103	
4100857 Extreme obesity with alveolar hypoventilation	122	129,478	39,878	652	3,17
4097996 Drug-induced obesity	112	25,632	1,737	97	64
380500 Hypertrophy of fat pad of knee	65	35,156		168	1,93
4029277 Fat pad syndrome	60	46,048	1,983	184	1,34
45757112 Obesity in mother complicating childbirth	38	144,328	114,934	102	92
4171147 Hypertrophic obesity				<10	
4217557 Simple obesity		1,325		305	
37018860 Severe obesity				341	

## Diagnosis Codes found in Claims

Cohort Diagnostics ≡					
hort Counts 🕕	_				
cidence Rate	ource Concepts 🔘 Standard C	oncepts			·
Show	25 v entries				Search:
me Distributions 👔 🕕	Subjects	Concept ID 🕴 Vocabulary	Code	Name	
cluded (Source) Concepts 👔	19,605,617	44833387 ICD9CM	278.00	Obesity, unspecified	
	17,834,064	35207024 ICD10CM	E66.9	Obesity, unspecified	
phan (Source) Concepts 🛛 🕕	9,811,519	45600659 ICD10CM	E66.01	Morbid (severe) obesity due to excess calories	
lex Event Breakdown 👔	7,468,759	44831059 ICD9CM	278.01	Morbid obesity	
	4,269,356	45590751 ICD10CM	Z68.41	Body mass index (BMI) 40.0-44.9, adult	
tabase information	3,967,904	45566451 ICD10CM	Z68.30	Body mass index (BMI) 30.0-30.9, adult	
	3,586,812	45600348 ICD10CM	Z68.31	Body mass index (BMI) 31.0-31.9, adult	
abase	3,448 <mark>,481</mark>	45591051 ICD10CM	E66.09	Other obesity due to excess calories	
QVIA_OpenClaims	3,287,955	45595538 ICD10CM	Z68.32	Body mass index (BMI) 32.0-32.9, adult	
	2,922,107	45547336 ICD10CM	Z68.33	Body mass index (BMI) 33.0-33.9, adult	
hort (Target)	2,665, <mark>556</mark>	45585849 ICD10CM	Z68.34	Body mass index (BMI) 34.0-34.9, adult	
COVID ID108 v1] Prevalen 🛛 🗸	2,450,438	45566452 ICD10CM	Z68.35	Body mass index (BMI) 35.0-35.9, adult	
	2,130,222	45566453 ICD10CM	Z68.36	Body mass index (BMI) 36.0-36.9, adult	
ncept Set	2,058,281	45609963 ICD10CM	Z68.42	Body mass index (BMI) 45.0-49.9, adult	
obesity diagnoses 🗸 🗸	1,881 <mark>,6</mark> 60	45581058 ICD10CM	Z68.37	Body mass index (BMI) 37.0-37.9, adult	
	1,674,752	45609961 ICD10CM	Z68.38	Body mass index (BMI) 38.0-38.9, adult	
	1,557,146	45609962 ICD10CM	Z68.39	Body mass index (BMI) 39.0-39.9, adult	
	1,285,223	45576172 ICD10CM	Z68.43	Body mass index (BMI) 50.0-59.9, adult	
	1,258,400	44833167 ICD9CM	V85.41	Body Mass Index 40.0-44.9, adult	
	1,230,658	35207023 ICD10CM	E66.8	Other obesity	
	1,129,030	44826272 ICD9CM	V85.54	Body Mass Index, pediatric, greater than or equal to 95th percentile for age	
	964,519	44835553 ICD9CM	V85.30	Body Mass Index 30.0-30.9, adult	
	839,998	44834364 ICD9CM	V85.31	Body Mass Index 31.0-31.9, adult	
	759,353	44828615 ICD9CM	V85.32	Body Mass Index 32.0-32.9, adult	
	737,579	45568006 ICD10CM	099.213	Obesity complicating pregnancy, third trimester	

#### Missing codes, some missing for a reason

Count	Concept ID 🕴 Standard	🕴 Vocabulary	Code	Rame
7,474	2100973 S	CPT4	00797	Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; gastric restrictive procedure for morbid obesity
588	44819525	ICD9CM	278.8	Other hyperalimentation
244	2109000 S	CPT4	43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty
157	2109003 S	CPT4	43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption
154	2102458 S	CPT4	15821	Blepharoplasty, lower eyelid; with extensive herniated fat pad
125	2109002 S	CPT4	43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy
101	4149383 S	SNOMED	268551005	Obesity screening
101	44828608	ICD9CM	V77.8	Screening for obesity
85	2108468 S	CPT4	38520	Biopsy or excision of lymph node(s); open, deep cervical node(s) with excision scalene fat pad
79	2109004 S	CPT4	43848	Revision, open, of gastric restrictive procedure for morbid obesity, other than adjustable gastric restrictive device (separate procedure)
50	40664664 S	HCPCS	G0447	Face-to-face behavioral counseling for obesity, 15 minutes
47	2108999 S	CPT4	43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty
8	2102494 S	CPT4	15838	Excision, excessive skin and subcutaneous tissue (includes lipectomy); submental fat pad
5	2101698 S	CPT4	0156T	Laparoscopy, surgical; revision or removal of gastric stimulation electrodes, lesser curvature (ie, morbid obesity)

Showing 1 to 14 of 14 entries

Previous 1 Next

## Weight Codes found in EHR

Cohort Diagnostics	l≡.			
Cohort Counts 👔				
Incidence Rate 👔	<ul> <li>Source Concepts O Standard Concepts</li> <li>Show 25 v entries</li> </ul>			Search:
Time Distributions 🕕 🕕	Subjects	Concept ID 🖗 Vocabulary	🗘 Code	Name A
Included (Source) Concepts	12,135,823	3025315 LOINC	29463-7	Body weight
	1,697	3013762 LOINC	3141-9	Body weight Measured
Orphan (Source) Concepts 👔 👔		3023166 LOINC	3142-7	Body weight Stated
Index Event Breakdown 🕕 🕕	Showing 1 to 3 of 3 entries			Previous 1 Next
Database information Database VA-OMOP Cohort (Target) [COVID ID108 v1] Prevalen Concept Set body weight V				<ul> <li>Vital Signs         Physiologic measurements of a patient that             indicate the status of the body's life sustaining             functions.         Diastolic blood pressure             Systolic blood pressure             Body height             Body weight             Heart Rate             Respiratory rate             Body temperature             Pulse oximetry</li></ul>
				Inhaled oxygen concentration BMI Percentile (2 - 20 years) Weight-for-length Percentile (Birth - 36 Montl Head Occipital-frontal Circumference (Birth - Months)

#### What makes a phenotype portable?

- Uses data types that can be found across systems
- Includes codes that can be found across systems
- Uses logic that can be applied across systems

### Standards for required logic not well-defined

- Unlike data elements and terminologies, there is not a defining set of logical querying capabilities specified, eg
  - Temporal logic (+/- relative to index event)
  - Count of occurrences
  - Groupings (any/all, and or not)
- But hope can be found in the CMS electronic clinical quality measures (eCQMs) that are being transitioned to broad interoperability standards

#### What is an eCQM?

- Clinical Quality Measures are required reporting for all providers and hospitals that participate in Medicare/Medicaid
   Performance on these measures is tied to reimbursement
- Each CQM is defined by numerator and denominator cohorts
- An eCQM is a computable phenotype representing these cohorts to ensure consistency in the reporting processing
- They include a data model, code sets, and logic

### eCQMs' Logic is Expressed Using CQL (Clinical Quality Language)



Data Model: How to describe the patient's medical record data needed to calculate the measure

Expression Logic: How to calculate the result and evaluate the performance

Structure: The container and sections describing measure metadata, numerator<sup>®</sup>, denominator<sup>®</sup>, exclusions, exceptions



# Clinical Quality Language (CQL)

X starts 3 days before start Y

- HL7's CQL aims to be both human readable and machine interpretable
- Leverages both embedded and NLM VSAC value sets
- Has extensive date
   manipulation logic
- Gets compiled into a query execution mechanism such as FHIR<sup>1</sup>

[Encounter: "Ambulatory/ED Visit"] E with [Condition: "Acute Pharyngitis"] P such that P.onsetDateTime during E.period and P.abatementDate after end of E.period

Concept { Code '66071002' from "SNOMED-CT", Code '818.1' from "ICD-10-CM" Y display 'Type B viral hepatitis' Y display 'Type B viral hepatitis' Y display 'Type B viral hepatitis'

he fo	llowing diagrams dep	ict the union, in	ntersect, and except opera	tors for intervals:
	•			
			••	·•
•		•	••	••
	union		intersect	except

1. https://github.com/DBCG/cql\_engine

valueset "Flutter Diagnosis": '2.16.840.1.113883.3.117.1.7.1.202'
valueset "Warfarin Medication": '2.16.840.1.113883.3.117.1.7.1.232'
valueset "Face-to-face Encounter": '2.16.840.1.113883.3.464.1003.101.12.1048'
valueset "Office Visit": '2.16.840.1.113883.3.464.1003.101.12.1001'

♥ Code System Version ♥ Code System OID	▲ Code	✓ Description
SNOMED CT ®	5370000	Atrial flutter (disorder)
SNOMED CT ®	49436004	Atrial fibrillation (disorder)
SNOMED CT ®	440059007	Persistent atrial fibrillation (disorder)
SNOMED CT ®	440028005	Permanent atrial fibrillation (disorder)
SNOMED CT ®	429218009	History of maze procedure for atrial fibrillation (situation)
SNOMED CT ®	428076002	History of atrial flutter (situation)
SNOMED CT ®	427665004	Paroxysmal atrial flutter (disorder)
SNOMED CT ®	427665004	Paroxysmal atrial fibrillation (disorder)
SNOMED CT ®	426814001	Transient cerebral ischemia due to atrial fibrillation (disorder)
SNOMED CT ®	426749004	Chronic atrial fibrillation (disorder)
SNOMED CT ®	425615007	Chronic atrial flutter (disorder)
SNOMED CT ®	425615007	Chronic atrial fibrillation (disorder)
SNOMED CT ®	314208002	Rapid atrial fibrillation (disorder)
SNOMED CT ®	312442005	History of - atrial fibrillation (situation)
SNOMED CT ®	300996004	Controlled atrial fibrillation (disorder)
SNOMED CT ®	282825002	Paroxysmal atrial fibrillation (disorder)
SNOMED CT ®	233911009	Non-rheumatic atrial fibrillation (disorder)
SNOMED CT ®	233910005	Lone atrial fibrillation (disorder)
SNOMED CT ®	195082009	Atrial fibrillation and flutter NOS (disorder)
SNOMED CT ®	195080001	Atrial fibrillation and flutter (disorder)
SNOMED CT ®	164890007	Electrocardiogram: atrial flutter (finding)
SNOMED CT ®	164889003	Electrocardiogram: atrial fibrillation (finding)

define "ActiveWarfarinDuringLookback":

"WarfarinMedications" M where M."effectiveTimePeriod" overlaps "LookbackInterval"

lefine "WarfarinUsageIntervals":

collapse

"ActiveWarfarinDuringLookback" M

return M."effectiveTimePeriod" intersect "LookbackInterval"

define "WarfarinUsage": Sum("WarfarinUsageIntervals" I return duration in days of I)

valueset "Flutter Diagnosis": '2.16.840.1.113883.3.117.1.7.1.202'
valueset "Warfarin Medication": '2.16.840.1.113883.3.117.1.7.1.232'
valueset "Face-to-face Encounter": '2.16.840.1.113883.3.464.1003.101.12.1048'
valueset "Office Visit": '2.16.840.1.113883.3.464.1003.101.12.1001'
valueset "Valvular Heart Disease": '2.16.840.1.113883.3.464.1003.104.12.1017'
valueset "INR Lab Result": '2.16.840.1.113883.3.117.1.7.1.213'
parameter MeasurementPeriod default Interval[DateTime(2013, 1, 1, 0, 0, 0, 0), DateTime(2014, 1, 1, 0, 0, 0, 0))

context Patient

define "FlutterDiagnoses": ["Condition": "Flutter Diagnosis"]
define "WarfarinMedications": ["MedicationAdministration": "Warfarin Medication"]
define "FaceToFaceEncounters": ["Encounter": "Face-to-face Encounter"]
define "OfficeVisitEncounters": ["Encounter": "Office Visit"]
define "ValvularHeartDiseaseDiagnoses": ["Condition": "Valvular Heart Disease"]
define "INRLabResults": ["Observation": "INR Lab Result"]

```
define "InDemographic":
    AgeInYearsAt(start of MeasurementPeriod) >= 18
```

define "InpatientEncounters": "FaceToFaceEncounters" union "OfficeVisitEncounters" define "ActiveFlutterDiagnoses": "FlutterDiagnoses" F where Interval[F."onsetDateTime", F."abatementDate"] overlaps before MeasurementPeriod define "ActiveValvularHeartDiseaseDiagnoses": "ValvularHeartDiseaseDiagnoses" D where Interval[D."onsetDateTime", D."abatementDate"] overlaps before MeasurementPeriod

define "LookbackInterval": Interval[start of MeasurementPeriod - 200 days, start of MeasurementPeriod]

define "ActiveWarfarinDuringLookback":
 "WarfarinMedications" M where M."effectiveTimePeriod" overlaps "LookbackInterval"

define "WarfarinUsageIntervals": collapse "ActiveWarfarinDuringLookback" M return M."effectiveTimePeriod" intersect "LookbackInterval"

define "WarfarinUsage": Sum("WarfarinUsageIntervals" I return duration in days of I)

#### Sharing code sets with VSAC across platforms



Leveraging Value Sets from the Value Set Authority Center (VSAC) in a Standards-**Based Clinical Data Repository** Richard Kiefer<sup>1</sup>, Luke V, Rasmussen<sup>2</sup>, Jennifer A, Pacheco<sup>2</sup>, Peter Speltz<sup>3</sup>, Joshua C, Denny<sup>3</sup>, Wil

ine, Rochester, MN; 2 Northwestern Uni Weill Cornell Med

emerge	network	<
ELECTRONIC MEDIC	CAL DECODDS & CENO	N

README.md

#### VSAC to OMOP

This is a command-line utility that takes a Value Set Authority Center (VSAC) OID for a particular value set, and usin the NLM's FHIR API, retrieves the value set definition including codes. It then communicates using the OHDSI Web/ to create the value set (as a concept set) and populate it with all codes that it is able to find.

#### Configuration

Currently the program uses a properties file found at config/config.properties . This will be changed in the future use command line options. For now, you should set the following options within that file:

UMLS_USER=username	Your UMLS username
UMLS_PASS=password	Your UMLS password
FHIR_URL=cts.nlm.nih.gov/fhir/	Note the lack of http(s) in front
VS_NAME=Acute Myocardial Infarction	The name of the value set you wish to load
VS_OIDS=2.16.840.1.113883.3.67.1.101.1.317	The VSAC OID of the value set you wish to load
VS_VER=20170609	The Definition Version (found from the VSAC UI) of the value s
OMOP_BASE_URL=http://api.ohdsi.org/WebAPI/	The base WebAPI URL of the OHDSI instance you want to load to
OMOP_SOURCE=SYNPUF5PCT	The data source in OHDSI
OMOP_CREATE=true	If the value set should actually be created or not.

FHIR <sup>®</sup> Terminology Service for VSAC Resources	
The FHIR Terminology Service for VSAC Resources is a RESTful API service for accessing the VS	AC value sets and supported code systems.

#### VSAC SVS API

leill Corr

The VSAC SVS API is based on the IHE SVS Technical Framework, section 2.2.21 Sharing Value Set Integration Profile (SVS), and the IHE SVS XML Schema

	Base URI: <u>https://cts.nlm.nih.gov/fhir</u>					
			annot retrieve intensional value sets. Use the <u>SVS API</u> to retrieve intensional value sets. pecified as a VSAC value set OID. Value set names are not unique in VSAC.			
	FHIR Resource	FHIR Operation	Examples			
ing	<u>ValueSet</u>		https://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1090			
bAPI		Sexpand	https://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1090/Sexpand			
			https://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1090/Sexpand?filter=Ankylos			
		<u>Svalidate-code</u>	https://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1090/§validate-code?system=http://hl7.org/fhir/sid/icd-			
	CodeSystem	Slookup	https://cts.nlm.nih.gov/fhir/CodeSystem/Slookup2system=http://loinc.org&code=1963-8			
re to			https://cts.nlm.nlh.gov/fhir/CodeSystem/\$lookup?system=http://loinc.org&code=1963-8&version=2.56			
			https://cts.nlm.nih.gov/fhir/CodeSystem/Slookup?system=http://loinc.org&code=1963-8&date=20150501			
		<u>Ssubsumes</u>	https://cts.nlm.nih.gov/fhir/CodeSystem/Ssubsumes?system=http://snomed.info/sct&codeA=29857009&codeB=10000006			
			https://cts.nlm.nih.gov/fhir/CodeSystem/\$subsumes?system=http://hl7.org/fhir/sid/icd-10-cm&version=2018&codeA=A01.01&code			

#### Sharing code sets with VSAC across platforms

Welcome Search	Value Sets Authoring	Collaboration Manageme	nt Download		Q. Browse Code Systems Ø Help	
Value Set Definitio	ns Medication *					
Harmonization     Harmonization     Cone	OID: 2.16.840.1.113762.1.4 AUTHOR Steward: VSAC ST Metadata Definition Approve Reject	FEWARD			schemic Stroke at Hospital Discharge Author: VSAC-	
Selease •	Definition Version: Draft • Code System(s):	Status: Proposed Code System Version (2):		Search Code System (2) Query: heparin	Filter By VSAC Author Registrati	
	RXINORM Value Set Code List	2018-11	0	Include inactive col Only Criteria: heparin	What is a VSAC author, steward or gro	
				Are you a brand new VSAC author or s		teward and need to create new groups?
	Injectable So	um, porcine 10 UNT/ML um, porcine 10 UNT/ML	SCDC Prescribi Active SCD Generic, Active	• henarin	Subject: VSAC Authoring Permissions	"Write to the help desk" button, and type the following text for these fields:
	1361036 [Hepflush] 1361038 10 ML hepar UNT/ML Inje	in sodium, porcine 10 ction [Hepflush] um, porcine 10 UNT/ML	SBDC Prescribi Active SBD Prescribi Active SBDC Prescribi Active	1361029 10 UNT/ Solution 1361036 heparin 10 UNT/	Description (required): Copy and paste the     1. Your UMLS user name:	following questions into the description field of the e-mail form, and provide your answers in the same field.
	1361047 heparin sodi 1361048 heparin sodi Injectable So	um, porcine 100 UNT/ML um, porcine 100 UNT/ML Jution	SCDC Prescrib: Active SCD Generic: Active	10 ML ht 1361038 porcine Injectior 1361042 heparin 10 UNT/	2. Your e-mail address: 3. Your organization:	
		Page 1 of 1 20	View 1-2 of 2	1361047 heparin 100 UN1 heparin 1361048 100 UN1	5. VSAC stewards approve value sets f	ets. Do you require value set authoring permissions? - Yes/No or publication. Do you require steward permissions? - Yes/No developing value sets? Include the URL for your program or activity. Note that the program or activity name will be reflected in
				Solution 1361218 heparin 100 UN 1361225 heparin 1000 UN	your author/steward group names.	ail, and phone # for the program or activity noted in #6:
				1000 01	9. If you answered YES to #8, please er	person be acting as a Steward, providing direct VSAC oversight to your authoring work in the VSAC? sure the contact person (Steward) also requests VSAC Authoring access. When your Steward applies for VSAC Authoring working with them as an Author, a Steward, or both, depending on your working arrangement.

#### Do you need to join an existing group?

Current group members can add you to the group. See the Group Management page for instructions.

### Logic Beyond Structured Data

- Many of the most critical data elements for determining cohort inclusion come from unstructured data
- As noted, USCDI mandates that systems be able to output a core set of 8 common and valuable clinical note types
- But how to cull data from clinical notes while conforming to the broader phenotype structure?

#### Many Valid Approaches

- Using NLP to prepopulate structured fields

   Eg OMOP Note table → NLP Derived fields in structured tables
- Using NLP in real-time queries to augment structured feature definition
  - Eg "Stroke" = {Stroke Codeset} OR {[occlusion OR ischemia] on Head CT}
- Using NLP in real-time queries to create unstructured features
  - Eg "> 2cm lung mass" = MeasurementFinder ({mass OR lesion} on Chest XR/CT) value >20 mm

In all cases, you must be able to integrate the NLP derived features back into the logical pipeline for structured data. @GT we use ClarityNLP to hybridize structured features (via CQL) and unstructured features (via NLPQL).

http://github.com/claritynlp

He J, Mark L, Hilton C, Martin J, Baker J, Duke J, Hui SL, Li X, Dexter P. A comparison of structured data query methods versus natural language processing to identify metastatic melanoma cases from electronic health records. International Journal of Computational Medicine and Healthcare. 2019;1(1):101-11.

#### How can you assess portability?

- In the absence of markedly different baseline populations, a portable phenotype should create comparable patient populations across sites
- That is, a group of patients who have a similar clinical condition should look more or less the same

# Spotlight: OHDSI Cohort Characterization

Cohort	СЛІМС		IQVIA_OpenClaims		CDM_Premier_COVID_v1240		STARR-OMOP		VA-OMOP	
Conort	Entries	Subjects	Entries 🕴	Subjects	Entries 🍦	Subjects	Entries	Subjects	Entries	Subjects
[COVID ID100 v1] Prevalent Type 2 Diabetes Mellitus	229,1 <mark>96</mark>	229, <mark>196</mark>	55,299,457	55,299,457	5,294,334	5,294,334	236,742	118, <mark>371</mark>	3,692,023	3,692,023
[COVID ID101 v1] Prevalent hypertension	598,064	598,064	122,784,203	122,784,203	12,336,370	12,336,370	621,640	310,820	8,033,128	8,033,128
[COVID ID102 v1] Prevalent chronic kidney disease	61,060	61,060	16,310,729	16,310,72 <mark>9</mark>	407,057	407,057	40,109	40,10 <mark>9</mark>	1,334,789	1,334,7 <mark>89</mark>
[COVID ID103 v1] Prevalent end stage renal disease	25,136	25,136	4,245,352	4,245,352	302,356	302,356	13,262	13,262	306,344	306,344
[COVID ID104 v1] Prevalent heart disease	607,680	607,680	87,858,660	87,858,660	6,742,394	6,742,394	270,169	270,169	5,737,199	5,737,199
[COVID ID105 v1] Prevalent malignant neoplasm excluding non-melanoma skin cancer	422,372	422,372	40,027, <mark>369</mark>	40,027 <mark>,369</mark>	3,122,450	3,12 <mark>2,450</mark>	183, <mark>139</mark>	183,139	3,03 <mark>3,30</mark> 3	3,03 <mark>3,303</mark>
[COVID ID106 v1] Prevalent Human immunodeficiency virus infection	16,417	16,417	1,349,258	1,349,258	35,096	35,096	2,259	2,259	53,978	53,978
[COVID ID107 V1] Prevalent Hepatitis C	21,250	21,250	3,658,562	3,658,562	285,341	285,341	12,835	12,835	463,484	463,484
[COVID ID108 v1] Prevalent obesity	431,821	431,821	53,718,965	53,7 <mark>18,965</mark>	3,617,717	3,6 <mark>17,717</mark>	357,490	357,490	3,49 <mark>9,354</mark>	3,4 <mark>99,354</mark>
[COVID ID109 v1] Prevalent Dementia	52,645	52,645	10,684,811	10,684,811	774,074	774,07 <mark>4</mark>	13,901	13,901	851,901	851,90 <mark>1</mark>
[COVID ID106 v1] Prevalent tuberculosis	642	642	15,649	15,649	1,114	1, <mark>1</mark> 14	345	345	5,380	5,380
[COVID ID118 v1] Prevalent Autoimmune condition	200,518	200,5 <mark>18</mark>	36,453,5 <mark>32</mark>	36,453, <mark>532</mark>	1,500,146	1,500,1 <mark>46</mark>	92,62 <mark>0</mark>	92,6 <mark>20</mark>	1,728,469	1,728, <mark>469</mark>
[COVID ID119 V1] Prevalent chronic obstructive pulmonary disease (COPD) without asthma	119,993	119,99 <mark>3</mark>	31,326,1 <mark>49</mark>	31,326, <mark>149</mark>	2,222,462	2,222, <mark>462</mark>	94,796	47,39 <mark>8</mark>	2,970 <mark>,93</mark> 6	2,97 <mark>0,936</mark>
[COVID ID120 V1] Prevalent Asthma without COPD	253, <mark>686</mark>	253, <mark>686</mark>	55,525,684	55,5 <mark>25,684</mark>	2,477,682	2,477 <mark>,682</mark>	246,340	123, <mark>170</mark>	733,011	733,011
[COVID ID125 V1] Prevalent pre-existing condition of COVID risk factor	1,055,017	1,055,017	138,902,076	138,902,076	12,031,423	12,031,423	482,561	482,561	8,011,205	8,011,205
[COVID ID199 V1] Pregnant women	312,562	178,8 <mark>18</mark>	39,893, <mark>561</mark>	23,813,7 <mark>63</mark>	1,114,14 <mark>5</mark>	1,083,71 <mark>6</mark>	85,085	61,33 <mark>8</mark>	60,250	42,098
[COVID ID200 v1] Flu-like symptom episodes	532,684	307 <mark>,207</mark>	182,421,964	96,488,751	9,099,499	7,786,607	459,834	256,291	3,571,173	1,869, <mark>676</mark>
[COVID ID203 v1] Prevalent chronic kidney disease broad	125,098	125,09 <mark>8</mark>	25,275,744	25,275,7 <mark>44</mark>	2,267,496	2,267, <mark>496</mark>	72,042	72,042	1,925,292	1,925, <mark>292</mark>
[COVID ID204 v1] Prevalent end stage renal disease broad	56,902	56,902	6,655,206	6,655,206	374,252	374,252	25,563	25,563	735,648	735,648
[COVID ID121 v1] Prevalent Human immunodeficiency virus infection broad	23,187	23,187	1,796,443	1,796,443	141,194	141,194	3,010	3,010	66,111	66,111
[COVID ID102 v1] Prevalent tuberculosis broad	15,078	15,078	504,836	504,836	5,682	5,682	2,348	2,348	41,746	41,746

Showing 1 to 21 of 21 entries

Previous 1 Next

#### 'Asthma' Incidence Rates Across Sites



#### 'Heart Disease' Incidence Rates Across Sites



#### Comorbidities for `Influenza` Patients

Covariate Name	IBM_CCAE	OPTUM_EXTENDED_DOD	OPTUM_PANTHER	
	Proportion	Proportion	Proportion	
Medical history: General				
Acute respiratory disease	34.4%	33.7%	18.5%	
Attention deficit hyperactivity disorder	1.5%	1.2%	0.8%	
Chronic liver disease	3.3%	3.9%	3.0%	
Chronic obstructive lung disease	4.5%	11.6%	9.5%	
Crohn's disease	1.5%	2.0%	1.3%	
Dementia	0.2%	1.2%	0.9%	
Depressive disorder	13.6%	18.9%	15.7%	
Diabetes mellitus	13.5%	20.9%	15.0%	
Gastroesophageal reflux disease	13.7%	21.9%	18.4%	
Gastrointestinal hemorrhage	3.3%	4.4%	2.3%	
Human immunodeficiency virus infection	0.2%	0.2%	0.2%	
Hyperlipidemia	30.6%	45.9%	31.2%	
Hypertensive disorder	34.8%	51.4%	38.4%	
Lesion of liver	0.8%	1.3%	1.0%	
Obesity	9.5%	12.9%	12.3%	
Osteoarthritis	44.4%	56.4%	37.0%	
Pneumonia	4.0%	6.2%	5.1%	
Psoriasis	7.7%6	7.3%	3.8%	
Renal impairment	2.8%	9.8%	6.9%	
Rheumatoid arthritis	85.7%	85.7%	83.4%	
Schizophrenia	0.1%	0.1%	0.2%	
Ulcerative colitis	1.5%	1.9%	1.2%	
Urinary tract infectious disease	10.7%	14.1%	6.4%	
Viral hepatitis C	1.1%	1.7%	1.6%	
Visual system disorder	28.8%	42.9%	17.0%	
Iedical history: Cardiovascular disease				
Atrial fibrillation	1.3%	4.4%	4.0%	
Cerebrovascular disease	2.5%	5.6%	3.19	
Coronary arteriosclerosis	4.6%	10.7%	8.5%	
Heart disease	15.0%	26.4%	20.5%	
Heart failure	2.0%	6.0%	4.5%	

### Medication Use for `Influenza` Patients

Attbacterials for systemic use       66.9%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%       -63.7%	Medication use			
Attidepressants       36.5%       36.4%       36.4%       36.4%         Antiepleptics       20.9%       23.8%       25.8%       25.8%         Antiinflammatory and antirheumatic products       65.8%       40.5%       40.2%         Antipoleptics       39.6%       40.5%       40.2%         Antipoleptic agents       39.6%       40.5%       40.2%         Antipole agents       7.4%       11.1%       23.2%       20.9%         Calcium chanei blockers       11.8%       11.7%       23.2%       20.9%         Dirugs for acid related disorders       11.8%       11.7%       23.2%       20.9%         Dirugs for acid related disorders       11.8%       11.7%       23.2%       20.9%         Dirugs for acid related disorders       11.8%       11.9%       23.2%       20.9%         Dirugs for acid related disorders       11.8%       30.9%       20.9%       20.9%         Dirugs for acid related disorders       10.7%       30.9%       20.9%       20.9%         Dirugs for acid related disorders       10.7%       30.9%       30.9%       30.9%       30.9%       30.9%       30.9%       30.9%       30.9%       30.9%       30.9%       30.9%       30.9%       30.9%       30	Agents acting on the renin-angiotensin system	24.9%	33.5%	31.5%
Antepleptics20.9%23.8%23.8%25.9%Antineoplastic agents39.6%40.5%40.5%40.2%Antipopriatics1.1%40.5%40.5%40.2%Antinonobic agents7.4%11.7%23.2%20.9%Beta blocking agents6.1%23.2%27.9%28.8%Calciur channel blockers14.4%30.6%36.8%36.8%Drugs for cald related disorders24.4%30.6%36.8%36.8%Drugs for cald related disorders29.7%36.8%36.8%36.8%Drugs seed in diabetes10.7%14.6%36.8%36.8%Inunosoppressants29.3%40.7%43.8%36.8%Lipid nodifying agents29.3%36.8%36.8%36.8%Opids32.9%32.8%36.8%36.8%36.8%Drugs for cald related sorter32.8%36.8%36.8%36.8%Drugs for cald related sorter36.8%36.8%36	Antibacterials for systemic use	66.9%	66.3%	42.8%
Attinfammatory and antirheumatic products       56.8%       59.4%       59.4%       59.4%       59.4%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%       40.2%	Antidepressants	36.5%	36.4%	36.4%
Attineoplastic agents       38.6%       40.5%       40.5%       40.5%         Attiporiatics       1.1%       1.0%       0.0%         Attithrombotic agents       7.4%       11.7%       32.0%       22.0%       27.0%         Calcium channel blockers       11.4%       23.2%       27.0%       28.5%       27.0%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%       28.5%	Antiepileptics	20.9%	23.8%	25.2%
Antiportatics       1.99       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199       .199 </td <td>Antiinflammatory and antirheumatic products</td> <td>65.8%</td> <td>59.4%</td> <td>55.9%</td>	Antiinflammatory and antirheumatic products	65.8%	59.4%	55.9%
Arthrombotic agents       7.4%       11.7%       32.0%         Beta blocking agents       16.1%       23.2%       27.0%         Calcium channel blockers       11.4%       17.0%       26.0%         Diuretics       24.4%       30.0%       28.5%         Drugs for acid related disorders       33.5%       35.8%       36.6%         Drugs for obstructive airway diseases       29.7%       30.4%       36.6%         Drugs used in diabetes       10.7%       14.8%       56.8%         Immunosuppressants       54.2%       54.3%       51.8%         Opiolds       23.3%       35.8%       35.8%       35.8%         Opiolds       33.6%       29.7%       54.9%       51.8%         Opiolog       32.8%       35.8%       35.8%       35.8%       35.8%         Opiolog       32.9%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8%       35.8% <td< td=""><td>Antineoplastic agents</td><td>39.6%</td><td>40.5%</td><td>40.2%</td></td<>	Antineoplastic agents	39.6%	40.5%	40.2%
Beta blocking agents       16.1%       23.2%       27.0%         Calcium channel blockers       11.4%       17.0%       16.8%         Diuretics       24.4%       30.0%       28.5%         Drugs for acid related disorders       33.5%       35.8%       46.0%         Drugs sort obstructive airway diseases       29.7%       30.4%       36.6%         Drugs used in diabetes       10.7%       14.6%       36.6%         Lipid modifying agents       54.2%       54.9%       57.8%         Opioids       23.3%       33.1%       57.8%         Phycholeptics       33.7%       33.1%       31.7%	Antipsoriatics	1.1%	1.0%	0.7%
Calcium channel blockers       11.4%       17.0%       16.8%         Diuretics       24.4%       30.0%       28.5%         Drugs for acid related disorders       33.5%       35.8%       46.0%         Drugs for obstructive airway diseases       29.7%       30.4%       36.6%         Drugs used in diabetes       10.7%       14.6%       15.8%         Immunosuppressants       54.2%       54.9%       57.8%         Opiolds       23.3%       33.1%       31.7%         Opiolds       40.7%       43.3%       41.0%         Psycholeptics       33.7%       32.8%       35.8%	Antithrombotic agents	7.4%	11.7%	32.0%
Diuretics       30.0%       28.5%         Drugs for acid related disorders       33.5%       35.8%       46.0%         Drugs for obstructive airway diseases       29.7%       30.4%       36.6%         Drugs used in diabetes       10.7%       14.6%       56.8%       15.8%         Immunosuppressants       54.2%       54.9%       54.9%       57.8%         Opiolds       40.7%       33.1%       31.1%       31.1%         Opiolds       33.6%       33.6%       31.1%       31.1%       31.1%	Beta blocking agents	16.1%	23.2%	27.0%
Drugs for acid related disorders       33.5%       35.8%       46.0%         Drugs for obstructive airway diseases       29.7%       30.4%       36.6%         Drugs used in diabetes       10.7%       14.6%       15.8%         Immunosuppressants       54.2%       54.9%       54.9%       51.7%         Lipid modifying agents       23.3%       33.1%       31.1%       31.7%         Opioids       40.7%       32.4%       32.4%       31.0%	Calcium channel blockers	11.4%	17.0%	16.8%
Drugs for obstructive airway diseases       29,7%       30,4%       36,6%         Drugs used in diabetes       10,7%       14,6%       15,8%         Immunosuppressants       54,2%       54,9%       57,8%         Lipid modifying agents       23,3%       33,1%       31,7%         Optiolds       40,7%       43,3%       41,0%         Psycholeptics       33,7%       32,4%       35,2%	Diuretics	24.4%	30.0%	28.5%
Drugs used in diabetes         10.7%         14.6%         15.6%           Immunosuppressants         54.2%         54.9%         57.8%           Lipid modifying agents         23.3%         33.1%         33.1%         31.7%           Opiolds         40.7%         43.3%         41.0%         32.4%         32.4%         32.4%         32.4%         35.2%         32.4%         35.2%         32.4%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2%         35.2% <td>Drugs for acid related disorders</td> <td>33.5%</td> <td>35.8%</td> <td>46.0%</td>	Drugs for acid related disorders	33.5%	35.8%	46.0%
Immunosuppressants54.2%54.9%57.8%Lipid modifying agents23.3%33.1%31.7%Opioids40.7%43.3%41.0%Psycholeptics33.7%32.4%35.2%	Drugs for obstructive airway diseases	29.7%	30.4%	36.6%
Lipid modifying agents     23.3%     33.1%     31.7%       Opioids     40.7%     43.3%     41.0%       Psycholeptics     33.7%     32.4%     35.2%	Drugs used in diabetes	10.7%	14.6%	15.8%
Opioids         40.7%         43.3%         41.0%           Psycholeptics         33.7%         32.4%         35.2%	Immunosuppressants	54.2%	54.9%	57.8%
Psycholeptics 33.7% 32.4% 35.2%	Lipid modifying agents	23.3%	33.1%	31.7%
	Opioids	40.7%	43.3%	41.0%
Psychostimulants, agents used for adhd and nootropics 5.7% 3.9% 4.4%	Psycholeptics	33.7%	32.4%	35.2%
	Psychostimulants, agents used for adhd and nootropics	5.7%	3.9%	4.4%

#### **Machine Learning Based Tools**



Journal of Biomedical Informatics Volume 97, September 2019, 103258



# PheValuator: Development and evaluation of a phenotype algorithm evaluator

Joel N. Swerdel <sup>a, b</sup> ♀ ⊠, George Hripcsak <sup>b, c</sup>, Patrick B. Ryan <sup>a, b, c</sup>



#### So how do we make phenotypes portable

- Use data types that can be found across systems

   Look across models and at emerging mandated standards
   Leverage the required data types
- Include codes that can be found across systems
  - Leverage cohort and dataset characterization tools
  - Publish concept sets on NLM VSAC for all to use
- Use logic that can be applied across systems
  - Avoid exotic logical operators
  - CQL capabilities can serve as a guide

### What makes a phenotype scalable?

- Meets all the criteria for portability and...
- There exists actual machinery to run the phenotype at a large number of sites



#### **PCORnet Coverage Map**

This map depicts the number of PCORI-funded Patient-Powered Research Networks (PPRNs) or Clinical Data Research Networks (CDRNs) that have coverage in each state.













#### Da Vinci 2020 Multi-Stakeholder Membership

Payers using CQL and FHIR



3

### How to improve Phenotype Scalability?

- It is not about phenotype design (ie portability)
- We need to make our phenotypes runnable in more places
- So yes continue to expand individual platform adoption

   simplify CDM ETL, code deployment, add value to participating organizations, publications, etc
- But we must take advantage of the transitions already underway in health systems and interoperability

### Keeping Both the Baby and the Bathwater

- When building phenotypes for your network, begin looking at a parallel pipeline to export logic using CQL, concept sets using VSAC codesets
- As FHIR mandates come into place and CQL becomes standard for health system payer interactions and reporting, you will have phenotypes that can piggyback on these technologies
- You can thus leverage a far broader range of sites as data partners (perhaps in an "Extended" tier) in addition to your native platform adopters

#### Caveats

- The aforementioned regulations are not internationally adopted at present and thus this pathway is US-centric
- Performance of patient-level technologies for population-level analytics will take time to catch up
- Culling data from a broader range of sites will introduce even more variability in populations and data quality that will need to be addressed



# Questions?

